Table 5. Odds ratios between prostate cancer death and study arm (screening vs control), by four estimation methods.
Estimation method |
||||
---|---|---|---|---|
Country | Empiricala | Empirical, corrected using overall estimates of adjudicator accuracyb | Empirical, corrected using differential estimates of adjudicator accuracy by study armc | Directly from latent class modeld |
Netherlands | 0.342 | 0.35 | 0.337 | 0.328 |
Belgium | 0.759 | 0.904 | 0.866 | 0.902 |
Sweden | 0.355 | 0.381 | 0.395 | 0.368 |
Finland | 0.52 | 0.575 | 0.568 | 0.556 |
Switzerland | 0.625 | 0.5 | 0.259 | 0.437 |
Estimated from cross-tabulation of adjudication consensus by study arm.
Estimated proportions of prostate cancer deaths in each study arm were corrected using estimated false positive and false negative adjudication rates in LCM 2. Odds ratio is then calculated from these corrected proportions.
Similar to approach (b), except that adjudicator accuracy was estimated from LCM 3.
Based on LCM 2 estimates of the association of study arm with the latent variable (prostate cancer death).